Ekso Bionics (NASDAQ:EKSO) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report issued on Monday. The brokerage set a “hold” rating on the stock.

Several other brokerages have also recently issued reports on EKSO. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Ekso Bionics in a research report on Tuesday, July 30th. Lake Street Capital began coverage on Ekso Bionics in a research report on Monday, June 24th. They issued a “buy” rating and a $2.50 target price on the stock.

Ekso Bionics Price Performance

NASDAQ EKSO opened at $1.23 on Monday. The company has a market capitalization of $22.59 million, a price-to-earnings ratio of -1.26 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.77 and a current ratio of 2.42. The stock has a 50-day moving average of $1.12 and a 200 day moving average of $1.23. Ekso Bionics has a one year low of $0.62 and a one year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last announced its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The firm had revenue of $4.95 million during the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same period in the previous year, the business posted ($0.31) earnings per share. On average, sell-side analysts forecast that Ekso Bionics will post -0.42 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC lifted its stake in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 596,050 shares of the company’s stock after acquiring an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is currently owned by institutional investors.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.